This study compared the efficacy, durability, and safety of faricimab to aflibercept for treating nAMD.
Key Findings:
- Both faricimab and aflibercept achieved similar improvements in vision over 2 years.
- Faricimab allowed for longer treatment intervals compared to aflibercept, with most patients achieving 16-week or 12-week dosing intervals by year 2.
- Safety profiles were comparable between the two drugs.
Implications:
- Faricimab could be a viable alternative to aflibercept for treating nAMD, potentially offering greater convenience due to less frequent injections.
- Further research is needed to determine the long-term safety and efficacy of faricimab in this patient population.
Disclaimer: This is a summary of the research and is not intended as medical advice. Please consult a qualified healthcare professional for diagnosis and treatment.
